Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: Results of a nationwide Spanish registry

Journal of Gastroenterology

Volumn 47, Issue 4, 2012, Pages 359-365

  Cabriada, J L ^a   Domenech E ^b,c   Ibargoyen, N ^d   Hernandez V ^e   Clofent, J ^f   Ginard, D ^g   Gutierrez Ibarluzea I ^d   Hinojosa, J ^f  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Basque Office for Health Technology Assessment (Osteba)   (Spain)

^e SERGAS UVigo   (Spain)

^f Hospital Manises   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Leukocytapheresis; Steroid dependence; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DATA BASE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LEUKAPHERESIS; LEUKOCYTAPHERESIS; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; REMISSION; SAFETY; SPAIN; STEROID DEPENDENT ULCERATIVE COLITIS; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKAPHERESIS; MALE; REMISSION INDUCTION; SPAIN; STEROIDS; TREATMENT OUTCOME;

EID: 84856286024     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0499-2     Document Type: Article

References (31)

1. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-9. (Pubitemid 46668255)
2. Travis SP, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62. (Pubitemid 351179488)
3. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-60. (Pubitemid 32729372)
4. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-30. (Pubitemid 43972900)
5. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53. (Pubitemid 41820634)
6. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30-year review. Gut. 2002;50:485-9. (Pubitemid 34638866)
7. López-Sanromán A, Bermejo F, Carrera E, García-Plaza A. Efficacy and safety of thiopurine immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther. 2004;20:161-6. (Pubitemid 38998213)
8. McCarthy DA, Rampton DS. Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease Clin Exp Immunol. 1991;6:489-93.
9. Tibble JA, Sigthorson G, Bridger D. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22. (Pubitemid 30452574)
10. Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-8.
11. Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis. 2010;42:432-5.
12. Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-52. (Pubitemid 40040082)
13. Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, et al. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study. World J Gastroenterol. 2007;13: 2193-7. (Pubitemid 46851155)
14. Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocytemonocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:1286-95.
15. Cabriada JL, Domènech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, et al. Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2006;29:85-92. (Pubitemid 43293985)
16. Frønsdal KB, Facey K, Klemp M, Norderhaug IN, Mørland B, Røttingen JA. Health technology assessment to optimize health technology utilization: using implementation initiatives and monitoring processes. Int J Technol Asses Health Care. 2010;3:309-16.
17. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1-23. (Pubitemid 351179487)
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317: 1625-9. (Pubitemid 18010466)
19. Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-88.
20. Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol. 2006;12: 7568-77. (Pubitemid 46040566)
21. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400-9.
22. Habermalz B, Sauerland S. Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci. 2010;55:1421-8.
23. Thanaraj S, Hamlin PJ, Ford AC. Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol Ther. 2010;32:1297-306.
24. Ljung T, Thomsen O, Vatn M, Karlén P, Karlsen LN, Tysk C, et al. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007;42:221-7.
25. Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mössner J, Schreiber S, et al. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol. 2005;11: 7001-6. (Pubitemid 43126060)
26. D'Ovidio V, Meo D, Viscido A, Bresci G, Vernia P, Caprilli R. Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. World J Gastroenterol. 2011;17:1831-5.
27. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36-44. (Pubitemid 39179238)
28. Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004;20: 783-92. (Pubitemid 39319234)
29. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004;36:811-7. (Pubitemid 41070579)
30. Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, et al. An open-label prospective randomized multi-center study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990-5.
31. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003;1:28-35. (Pubitemid 37254469)